AgaMatrix, Inc.: Series C $23.7M

AgaMatrix (Salem, NH) maker of blood glucose monitoring systems that provide results to help users better manage their diabetes closed a $23.7M Series C financing. Participants include Ferrer Freeman & Co.

PeptImmune, Inc.: Series D $8.2M

PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Ventures and Silicon Valley Bank Capital.

Pervasis Therapeutics, Inc.: Series B $9.75M

Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participants include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

ProtAffin Biotechnologie, AG: Series B €4.0M

ProtAffin Biotechnologie (Austria) is focused on developing novel biotechnology therapeutic products for acute and chronic inflammatory diseases has closed a €4.0M Series A financing. Participants include The Entrepreneurs Fund BV, Aescap Venture Management and Z-Cube.

Aushon Biosystems, Inc.: Series B $7.0M

Aushon Biosystems (Burlington, MA) provides advanced microarray technologies to life science research, drug discovery, development and clinical diagnostics closed on a $4M traunche $7M Series B. Participant was North Bridge Venture Partners.

AmpliMed Corp.: Series C $22.0M

AmpliMed (Tucson, AZ) a clinical-stage pharmaceutical company with Phase II lead compounds for malignant melanoma and pancreatic cancer closed on $5M traunche of a $22M Series C financing. Participants include BioMed Venture Partners, Biotech Insight Ventures, Solstice Capital and Valley Ventures.

Autonomic Technologies, Inc.: Series A $5.0M

Autonomic Technologies (Menlo Park, CA) makers of neuromdoulation stimulation devices closed on the first $3M traunche of a $5M Series A financing. Participants in the round include Kleiner Perkins Caufield & Byers and the Cleveland Clinic.